Russia’s Sputnik V Demonstrates 91.4% Efficacy Against COVID-19

November 25, 2020 Auto Bot Biotech, reports, results, Sputnik V 0

Shots:

  • The ongoing P-lll study involves assessing of Sputnik V vaccine vs PBO in 40,000 patients in a ratio (1:3) with COVID-19. The efficacy of the vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose
  • Preliminary data from volunteers obtained 42days after the first dose (corresponds with 21days after the second dose) indicates the efficacy of the vaccine above 95%.
  • The data will be published by the Gamaleya Center team in peer-reviewed medical journals. Following the completion of P-lll clinical trials, Gamaleya Center will provide access to the full clinical trial report

Click here ­to­ read full press release/ article | Ref: Sputnik | Image: Anadolu Agency

The post Russia’s Sputnik V Demonstrates 91.4% Efficacy Against COVID-19 first appeared on PharmaShots.